Literature DB >> 9282961

A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease.

Z I Alam1, S E Daniel, A J Lees, D C Marsden, P Jenner, B Halliwell.   

Abstract

The degeneration of neurones in Parkinson's disease (PD) may involve oxidative stress. Previously, increased lipid peroxidation and oxidative DNA damage have been reported in parkinsonian substantia nigra. In the present study the protein carbonyl assay was used to assess oxidative protein damage in postmortem brain tissue from patients with PD and age-matched controls. In brain areas associated with PD, such as substantia nigra, caudate nucleus, and putamen, there was a significant increase in carbonyl levels. However, increased carbonyl levels were also found in areas of the brain not thought to be affected in PD. This perhaps suggests that protein carbonyl formation is related to therapy with L-DOPA, which can exert prooxidant properties in vitro. Consistent with this possibility, brain regions from individuals with incidental Lewy body disease (putative presymptomatic PD) showed no rise in carbonyls in any brain areas. Our data show that either oxidative protein damage occurs widely but late in PD brain, and/or that L-DOPA treatment contributes to protein oxidation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9282961     DOI: 10.1046/j.1471-4159.1997.69031326.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  154 in total

1.  Inhibition of rat brain microsomal cytochrome P450-dependent dealkylation activities by an oxidative stress.

Authors:  P Lagrange; R D El-Bachá; P Netter; A Minn
Journal:  Neurotox Res       Date:  2001-08       Impact factor: 3.911

Review 2.  Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.

Authors:  M Flint Beal
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

Review 3.  Reactive oxygen species in the regulation of synaptic plasticity and memory.

Authors:  Cynthia A Massaad; Eric Klann
Journal:  Antioxid Redox Signal       Date:  2010-10-28       Impact factor: 8.401

4.  Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease.

Authors:  M P Smith; W A Cass
Journal:  Neuroscience       Date:  2006-11-15       Impact factor: 3.590

Review 5.  Oxidative damage to macromolecules in human Parkinson disease and the rotenone model.

Authors:  Laurie H Sanders; J Timothy Greenamyre
Journal:  Free Radic Biol Med       Date:  2013-01-15       Impact factor: 7.376

Review 6.  Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

Authors:  Chun Zhou; Yong Huang; Serge Przedborski
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

7.  Astrocytic dynamin-like protein 1 regulates neuronal protection against excitotoxicity in Parkinson disease.

Authors:  Jake G Hoekstra; Travis J Cook; Tessandra Stewart; Hayley Mattison; Max T Dreisbach; Zachary S Hoffer; Jing Zhang
Journal:  Am J Pathol       Date:  2014-12-04       Impact factor: 4.307

8.  Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes.

Authors:  Yong Peng; Chengshan Wang; Howard H Xu; You-Nian Liu; Feimeng Zhou
Journal:  J Inorg Biochem       Date:  2009-11-18       Impact factor: 4.155

9.  Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells.

Authors:  Jun Tang Guo; An Qi Chen; Qi Kong; Hua Zhu; Chun Mei Ma; Chuan Qin
Journal:  Cell Mol Neurobiol       Date:  2007-11-06       Impact factor: 5.046

10.  An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

Authors:  Todd B Sherer; Ranjita Betarbet; Amy K Stout; Serena Lund; Melisa Baptista; Alexander V Panov; Mark R Cookson; J Timothy Greenamyre
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.